Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AMLTo access our poster, please submit a completed form below.
A Phase 1b, Open-Label, 2-part, Safety, Tolerability, and Efficacy Study of a Soluble Beta-Glucan (Odetiglucan) in Combination with a CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During First-Line (1L) Chemotherapy
Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer models
Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
Combination therapy using PERK and PD1/PD-L1 inhibitors reprograms tumor associated macrophages and reduces tumor burden
Activation of GCN2 by HC-7366 results in significant anti-tumor efficacy as monotherapy and in combination with Venetoclax in AML models
Novel GCN2 Modulator HC-7366 Inhibits Myeloid-derived Suppressor Cells and Reduces Pulmonary Metastases
Perk Inhibitor HC-5404 Demonstrates Immune-activation and Anti-tumor Efficacy in Combination with Anti-PD1 Immune Checkpoint Inhibitor Antibody
Cancer immunotherapy via myeloid signaling pathway co-activation (Wattenberg et al. AACR Pancreatic Cancer 2022)
Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)